Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


suck pdf from google scholar
unlimited free pdf from europmc32205092    free
PDF from PMC    free
html from PMC    free
PDF vom PMID32205092  :  Publisher
PDF vom PMID32205092 :   free
PDF vom PMID32205092

suck abstract from ncbi

Nephropedia Template TP Text

Twit Text FOAVip

Twit Text #

English Wikipedia

  • TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib #MMPMID32205092
  • Wu D; Yang XO
  • J Microbiol Immunol Infect 2020[Jun]; 53 (3): 368-370 PMID32205092show ga
  • COVID-19 emerges as a pandemic disease with high mortality. Development of effective prevention and treatment is an urgent need. We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type immune profiles.
  • |Betacoronavirus/immunology[MESH]
  • |COVID-19[MESH]
  • |Coronavirus Infections/*drug therapy/pathology[MESH]
  • |Cytokine Release Syndrome/*drug therapy[MESH]
  • |Cytokines/biosynthesis/immunology[MESH]
  • |Humans[MESH]
  • |Janus Kinase 2/*antagonists & inhibitors[MESH]
  • |Pandemics[MESH]
  • |Pneumonia, Viral/*drug therapy/pathology[MESH]
  • |Pyrrolidines/*pharmacology[MESH]
  • |SARS-CoV-2[MESH]
  • |Sulfonamides/*pharmacology[MESH]
  • |Th17 Cells/*immunology[MESH]

  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    368 3.53 2020